In-vitro大腸がんスクリーニング検査市場- 世界の産業規模、動向、機会、予測、検査タイプ別、地域別、競合、2019年～2029年

世界のIn-vitro大腸がんスクリーニング検査市場は、2023年に8億6,460万米ドルと評価され、2029年までのCAGRは3.04%で、予測期間には堅調な成長が予測されています。

世界のIn-vitro大腸がんスクリーニング検査市場は、広範なヘルスケア産業の重要な構成要素です。大腸がんの早期発見と予防に役立つ様々な診断検査の開発と商品化が特徴です。

In-vitro大腸がんスクリーニング検査は、大腸がんに関連するバイオマーカー、遺伝子変異、その他の指標を検出するための生物学的サンプル（血液や便など）の分析を伴う。これらの検査は、早期段階で疾患を特定し、タイムリーな介入と患者の転帰の改善を可能にすることを目的としています。

市場促進要因

大腸がん罹患率および死亡率の上昇

スクリーニング技術の進歩

人口の高齢化

政府の取り組みと公衆衛生キャンペーン

主な市場課題

認識と患者関与の欠如

アクセスとヘルスケア格差

コンプライアンスとアドヒアランスの問題

主要市場動向

非侵襲的かつ血液ベースの検査へのシフト

個別化医療と遺伝子検査

人工知能（AI）とデータ分析の統合

セグメント別洞察

検査タイプ別洞察

地域別洞察

目次

第1章 概要

第2章 調査手法

第3章 エグゼクティブサマリー

第4章 顧客の声

第5章 世界のIn-vitro大腸がんスクリーニング検査市場展望

• 市場規模予測
  • 金額別
• 市場シェア予測
  • 検査タイプ別（便潜血検査、バイオマーカー検査、CRC DNAスクリーニング検査）
  • 地域別
  • 企業別（2023年）
• 市場マップ

第6章 北米のIn-vitro大腸がんスクリーニング検査市場の展望

• 市場規模予測
  • 金額別
• 市場シェア予測
  • 検査タイプ別
  • 国別
• 北米国別分析
  • 米国
  • カナダ
  • メキシコ

第7章 欧州のIn-vitro大腸がんスクリーニング検査市場の展望

• 市場規模予測
  • 金額別
• 市場シェア予測
  • 検査タイプ別
  • 国別
• 欧州国別分析
  • ドイツ
  • 英国
  • イタリア
  • フランス
  • スペイン

第8章 アジア太平洋地域のIn-vitro大腸がんスクリーニング検査市場の展望

• 市場規模予測
  • 金額別
• 市場シェア予測
  • 検査タイプ別
  • 国別
• アジア太平洋地域：国別分析
  • 中国
  • インド
  • 日本
  • 韓国
  • オーストラリア

第9章 南米のIn-vitro大腸がんスクリーニング検査市場の展望

• 市場規模予測
  • 金額別
• 市場シェア予測
  • 検査タイプ別
  • 国別
• 南米：国別分析
  • ブラジル
  • アルゼンチン
  • コロンビア

第10章 中東・アフリカのIn-vitro大腸がんスクリーニング検査市場の展望

• 市場規模予測
  • 金額別
• 市場シェア予測
  • 検査タイプ別
  • 国別
• MEA：国別分析
  • 南アフリカ
  • サウジアラビア
  • アラブ首長国連邦

第11章 市場力学

• 促進要因
• 課題

第12章 市場動向と発展

• 最近の動向
• 製品発表
• 合併・買収

第13章 In-vitro大腸がんスクリーニング検査の世界市場SWOT分析

第14章 競合情勢

• Abbott Laboratories, Inc.
• Beckman Coulter, Inc.
• Eiken Chemical Co., Ltd.
• Sysmex Corporation
• Siemens Healthineers AG
• Quest Diagnostics Incorporated
• Merck KGaA
• Kyowa Kirin Co., Ltd.
• Randox Laboratories Ltd.
• R-Biopharm AG

第15章 戦略的提言

第16章 免責事項

Global In-vitro Colorectal Cancer Screening Tests Market was valued at USD 864.60 million in 2023 and is anticipated to project robust growth in the forecast period with a CAGR of 3.04% through 2029. The global in-vitro colorectal cancer screening tests market is a critical component of the broader healthcare industry. It is characterized by the development and commercialization of various diagnostic tests that aid in the early detection and prevention of colorectal cancer.

In-vitro colorectal cancer screening tests involve the analysis of biological samples (such as blood or stool) to detect biomarkers, genetic mutations, or other indicators associated with colorectal cancer. These tests aim to identify the disease at an early stage, allowing for timely intervention and improved patient outcomes.

Key Market Drivers

Rising Colorectal Cancer Incidence and Mortality Rates

The rising incidence and mortality rates of colorectal cancer play a crucial role in driving the growth of the global in-vitro colorectal cancer screening tests market. Colorectal cancer is a significant global health concern, and its increasing prevalence has heightened the importance of early detection and regular screening. Colorectal cancer is one of the most common types of cancer globally. It affects the colon or rectum and can occur in various forms, such as adenocarcinoma, which is the most prevalent subtype. Incidence and mortality rates are critical metrics for assessing the disease burden. Incidence refers to the number of new cases diagnosed within a specific time frame, while mortality indicates the number of deaths due to colorectal cancer.

The World Cancer Research Fund reports that colorectal cancer is the third most commonly diagnosed cancer worldwide and the second leading cause of cancer-related deaths. The increasing incidence of colorectal cancer places a significant burden on healthcare systems, both in terms of costs and resources. Treating advanced-stage colorectal cancer is more complex and expensive than early-stage disease management. Hospitals and healthcare providers are increasingly recognizing the need to focus on prevention and early detection as a cost-effective approach to managing colorectal cancer, which underscores the importance of screening.

The rising incidence and mortality rates have prompted governments, healthcare organizations, and advocacy groups to raise awareness about colorectal cancer and the benefits of screening. Public health campaigns often emphasize the importance of early detection in improving patient outcomes and reducing mortality. These campaigns encourage individuals to undergo regular screenings, especially if they are at higher risk due to factors like age or family history. The increasing incidence of colorectal cancer creates a significant market opportunity for in-vitro colorectal cancer screening tests. As more people become aware of the disease and its risks, there is a higher demand for accessible and accurate screening methods. Healthcare providers, diagnostics companies, and laboratories have an incentive to develop and market innovative and reliable screening tests to cater to this growing demand.

Advancements in Screening Technologies

Advancements in screening technologies are a significant market driver for the global in-vitro colorectal cancer screening tests market. These technological innovations have led to more accurate, convenient, and accessible methods for detecting colorectal cancer, ultimately driving market growth. Advancements in screening technologies have led to tests with greater sensitivity and specificity. These tests can detect even small amounts of colorectal cancer-related biomarkers or abnormalities, reducing the likelihood of false negatives and false positives. Improved accuracy is essential for early detection, as it ensures that individuals at risk are more likely to receive a timely diagnosis and appropriate treatment.

Technological advancements have facilitated the development of non-invasive and minimally invasive colorectal cancer screening methods. These tests, such as blood-based tests and stool-based tests, are less uncomfortable and more convenient for patients compared to invasive procedures like colonoscopy. The availability of these options encourages individuals to undergo regular screening, as it reduces the perceived barriers associated with traditional screening methods. Advances in genomics and molecular biology have led to the identification of specific molecular and genetic biomarkers associated with colorectal cancer. Screening tests can now target these biomarkers to detect the disease. Molecular and genetic testing allows for more precise and personalized screening. It can identify individuals at higher risk due to genetic factors and enable tailored approaches to screening and prevention.

Liquid biopsies, a cutting-edge screening technology, involve analyzing a patient's blood for circulating tumor DNA (ctDNA) and other biomarkers associated with colorectal cancer. This approach is minimally invasive and offers the potential for early cancer detection. Liquid biopsies have the advantage of being less invasive, which can lead to higher patient compliance with screening recommendations. They also have the potential for monitoring treatment response and disease progression. Technological advancements in medical imaging have improved the visualization of colorectal abnormalities. Virtual colonoscopy (CT colonography) and advanced endoscopic techniques provide clearer and more detailed images of the colon. These imaging technologies help gastroenterologists and radiologists identify polyps, tumors, or other lesions with greater accuracy, enhancing early detection and diagnosis.

Aging Population

The aging population is a significant market driver for the global in-vitro colorectal cancer screening tests market. Colorectal cancer is more commonly diagnosed in individuals aged 50 and older, and as the global population continues to age, this demographic presents a growing target for screening and early detection. Colorectal cancer is predominantly an age-related disease, with the majority of cases diagnosed in individuals over the age of 50. The risk of developing colorectal cancer increases with age, making regular screening particularly important for older adults. As the global population ages, the number of individuals at higher risk for colorectal cancer naturally increases, leading to a greater demand for screening tests in this demographic.

Several factors related to aging contribute to the increased risk of colorectal cancer. These include cumulative exposure to environmental factors, genetic mutations, lifestyle choices, and physiological changes in the gastrointestinal tract. Age-related changes, such as the accumulation of genetic mutations and the slowing of cell repair mechanisms, make older individuals more susceptible to developing colorectal cancer. Healthcare providers and public health organizations recognize that early detection of colorectal cancer can lead to more successful treatment outcomes. As a result, they place a strong emphasis on regular screening for individuals aged 50 and older. This emphasis on early detection extends to both healthcare guidelines and public awareness campaigns, encouraging older adults to undergo screening, which contributes to the growing demand for in-vitro colorectal cancer screening tests.

The aging population offers a substantial market opportunity for in-vitro colorectal cancer screening tests. As more people enter the age group at risk, there is a natural increase in demand for screening methods. Healthcare providers and diagnostic companies can cater to this demographic by offering convenient and non-invasive screening tests that are designed to be accessible and comfortable for older individuals. Treating advanced-stage colorectal cancer can be more expensive and resource-intensive for healthcare systems. This has led healthcare systems to adopt a preventive approach by focusing on early detection and regular screening for older individuals, which can ultimately reduce the long-term healthcare costs associated with colorectal cancer.

Government Initiatives and Public Health Campaigns

Government initiatives and public health campaigns are crucial market drivers for the global in-vitro colorectal cancer screening tests market. These initiatives and campaigns are aimed at increasing awareness about colorectal cancer, promoting regular screening, and improving accessibility to screening tests. Government initiatives and public health campaigns are instrumental in educating the general population about colorectal cancer, its risk factors, and the importance of early detection. They provide information on the disease's prevalence, symptoms, and the benefits of regular screening.

By raising awareness, these campaigns ensure that people are well-informed about the disease, encouraging them to seek screening when necessary. Governments and healthcare organizations often develop and promote guidelines for colorectal cancer screening. These guidelines help healthcare providers and patients understand when and how to conduct screening. By setting clear recommendations, governments contribute to the standardization of screening practices, making it easier for healthcare providers to offer screening tests and for patients to access them. Some governments offer subsidized or free colorectal cancer screening programs to eligible populations. These programs can significantly reduce the financial barriers that may deter individuals from undergoing screening. By providing financial support, governments ensure that a broader range of individuals can access screening tests, which stimulates demand for in-vitro colorectal cancer screening tests. Public health campaigns often advocate for the use of non-invasive or minimally invasive colorectal cancer screening tests. These tests are more convenient and comfortable for patients, making them more likely to participate in screening. Government initiatives can incentivize healthcare providers to adopt these tests, further enhancing their popularity and accessibility.

Key Market Challenges

Lack of Awareness and Patient Engagement

One of the significant challenges facing the in-vitro colorectal cancer screening tests market is the lack of awareness among the general population regarding the importance of regular screening. Many individuals may not understand the risk factors, the need for early detection, or the availability of effective screening tests.

Overcoming this challenge requires substantial efforts in public education and awareness campaigns. Healthcare providers, governments, and advocacy groups need to invest in outreach programs to inform individuals about colorectal cancer, its prevalence, and the benefits of early screening. Encouraging patient engagement can also be difficult. Some people may feel uncomfortable or anxious about the screening process, and addressing these concerns is essential to boost participation rates.

Access and Healthcare Disparities

Disparities in access to healthcare and healthcare infrastructure can hinder the growth of the in-vitro colorectal cancer screening tests market. In many regions, especially in low- and middle-income countries, access to healthcare facilities, diagnostic tests, and specialized screening services is limited.

Even in high-income countries, there are disparities in healthcare access, with some underserved populations having limited access to healthcare services. This can lead to uneven screening rates and contribute to disparities in colorectal cancer outcomes. Addressing this challenge involves improving healthcare infrastructure and ensuring that screening tests are widely available, especially in underserved areas. Public and private sectors, along with international organizations, need to collaborate to reduce disparities in access.

Compliance and Adherence Issues

Patient compliance and adherence to colorectal cancer screening guidelines are significant challenges. While there are various screening options available, such as colonoscopy, fecal immunochemical tests, and stool DNA tests, patients may not consistently follow the recommended screening schedules.

Factors contributing to non-compliance include fear, discomfort, embarrassment, and the inconvenience associated with some screening methods. Individuals may also underestimate their risk or procrastinate, delaying the screening process. Improving compliance and adherence involves addressing these barriers by making screening tests more patient-friendly, offering non-invasive and more convenient options, and developing strategies for reminding and motivating individuals to follow through with screening recommendations. Healthcare providers can play a crucial role in patient education and follow-up.

Key Market Trends

Shift Towards Non-Invasive and Blood-Based Tests

A significant trend in the colorectal cancer screening market is the shift towards non-invasive and blood-based screening tests. Traditional methods like colonoscopy and sigmoidoscopy, while effective, can be invasive, uncomfortable, and costly. This has led to the development and adoption of less invasive alternatives.

Blood-based tests, also known as liquid biopsies, are gaining prominence. These tests analyze specific biomarkers or circulating tumor DNA in the blood to detect colorectal cancer. They offer a less invasive and more convenient option for patients, potentially increasing overall screening rates. Fecal-based tests, such as the fecal immunochemical test (FIT) and stool DNA tests, are also less invasive than traditional colonoscopy. These trends reflect a growing preference for more patient-friendly screening methods.

Personalized Medicine and Genetic Testing

Another significant trend in the colorectal cancer screening market is the incorporation of personalized medicine and genetic testing. Advances in understanding the genetic basis of colorectal cancer have led to the development of genetic screening tests.

Genetic tests can identify individuals with a higher risk of developing colorectal cancer based on their genetic profile. This allows for targeted and personalized screening strategies for those at elevated risk. Moreover, genetic testing can aid in identifying specific mutations or biomarkers associated with colorectal cancer, contributing to early detection and tailored treatment plans. These personalized approaches are becoming an integral part of the market's growth.

Integration of Artificial Intelligence (AI) and Data Analytics

The integration of artificial intelligence and data analytics is transforming the colorectal cancer screening market. AI algorithms are being applied to medical imaging, such as CT scans and colonoscopy videos, to assist in the detection of colorectal abnormalities, including polyps and tumors.

AI can help radiologists and gastroenterologists identify potential areas of concern, improving accuracy and reducing false positives and false negatives. This trend aims to enhance the diagnostic capabilities of healthcare providers and increase early detection rates. Data analytics play a critical role in population health management and screening program efficiency. Healthcare systems are using data to identify at-risk populations, monitor screening adherence, and evaluate the effectiveness of screening programs. These insights guide public health efforts and resource allocation.

Segmental Insights

Test Type Insights

Based on the category of Test Type, the Fecal occult blood test segment emerged as the dominant player in the global market for In-vitro Colorectal Cancer Screening Tests in 2023. FOBTs are highly cost-effective compared to other screening methods such as colonoscopy, sigmoidoscopy, or even some genetic tests. This makes them a practical choice for both healthcare providers and payers.

The relatively low cost of FOBTs ensures that they are accessible to a broad range of patients, including those in resource-constrained healthcare systems. This affordability encourages higher participation rates and broader adoption. FOBTs are non-invasive, which means they do not require any uncomfortable or invasive procedures. Patients can collect stool samples at home, which is significantly less intimidating than undergoing a colonoscopy. This non-invasive nature of FOBTs contributes to higher patient compliance and adherence to screening guidelines. It removes barriers associated with fear, discomfort, or embarrassment, which can be associated with more invasive methods.

FOBTs typically involve collecting a small sample of stool, which is relatively simple for patients to do in the privacy of their own homes. There is no need for dietary restrictions or bowel preparation, making the process less burdensome. The convenience and ease of sample collection encourage patients to follow through with regular screening, promoting early detection of colorectal cancer. FOBTs are designed to detect occult (hidden) blood in the stool, which can be an early sign of colorectal cancer. The presence of blood in the stool can be indicative of polyps or tumors, even before symptoms appear. FOBTs have been proven effective in identifying individuals at risk, allowing for early intervention and improved patient outcomes. They have demonstrated their ability to reduce colorectal cancer mortality when used in screening programs. These factors are expected to drive the growth of this segment.

Regional Insights

North America emerged as the dominant player in the global In-vitro Colorectal Cancer Screening Tests market in 2023, holding the largest market share in terms of value. North America has one of the highest colorectal cancer prevalence rates globally. The United States and Canada, in particular, report a significant burden of the disease. This high incidence of colorectal cancer drives the demand for screening tests. North America boasts a well-developed and comprehensive healthcare infrastructure. The availability of advanced medical facilities, diagnostic laboratories, and healthcare providers enhances the accessibility of colorectal cancer screening tests for the population. Public awareness campaigns, initiated by both government and non-profit organizations, play a pivotal role in promoting colorectal cancer screening. These campaigns have increased patient education and led to higher participation rates in screening programs. Government support in the form of subsidized screening programs, reimbursement policies, and clinical guidelines has made colorectal cancer screening more affordable and accessible for patients. This support has significantly boosted the adoption of in-vitro screening tests. The region is home to several prominent healthcare companies and diagnostic laboratories that are continually innovating and introducing advanced in-vitro colorectal cancer screening tests. This innovation keeps North America at the forefront of the market.

The Asia-Pacific market is poised to be the fastest-growing market, offering lucrative growth opportunities for In-vitro Colorectal Cancer Screening Tests players during the forecast period. Factors such as Asia-Pacific region has a large, underserved population with limited access to healthcare services. As awareness of colorectal cancer increases and healthcare access improves, there is a significant untapped market for screening tests in this region. Many countries in the Asia-Pacific region are increasing their investments in healthcare infrastructure, including diagnostics and cancer screening. This investment is expected to facilitate the growth of the colorectal cancer screening market. Changes in lifestyle, dietary patterns, and urbanization in the Asia-Pacific region have contributed to an increased risk of colorectal cancer. This shift in disease risk factors is expected to drive demand for screening tests. Colorectal cancer awareness campaigns and educational initiatives are gaining momentum in the Asia-Pacific region. These campaigns, often led by governments and non-governmental organizations, are expected to result in higher screening rates. Governments in countries such as China, India, and Japan are implementing colorectal cancer screening programs and guidelines, similar to those in North America. These initiatives will likely boost the market for in-vitro screening tests in the region.

Key Market Players

Abbott Laboratories, Inc.

Beckman Coulter, Inc.

Eiken Chemical Co., Ltd.

Sysmex Corporation

Siemens Healthineers AG

Quest Diagnostics Incorporated

Merck KGaA

Kyowa Kirin Co., Ltd.

Randox Laboratories Ltd.

R-Biopharm AG

Report Scope:

In this report, the Global In-vitro Colorectal Cancer Screening Tests Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

In-vitro Colorectal Cancer Screening Tests Market,By Test Type:

• Fecal Occult Blood Tests
• Biomarker tests
• CRC DNA Screening Tests

In-vitro Colorectal Cancer Screening Tests Market, By Region:

• North America
  • United States
  • Canada
  • Mexico
• Europe
  • France
  • United Kingdom
  • Italy
  • Germany
  • Spain
• Asia-Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea
• South America
  • Brazil
  • Argentina
  • Colombia
• Middle East Africa
  • South Africa
  • Saudi Arabia
  • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global In-vitro Colorectal Cancer Screening Tests Market.

Available Customizations:

Global In-vitro Colorectal Cancer Screening Tests market report with the given market data, Tech Sci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1.Product Overview

• 1.1.Market Definition
• 1.2.Scope of the Market
  • 1.2.1.Markets Covered
  • 1.2.2.Years Considered for Study
  • 1.2.3.Key Market Segmentations

2.Research Methodology

• 2.1.Objective of the Study
• 2.2.Baseline Methodology
• 2.3.Key Industry Partners
• 2.4.Major Association and Secondary Sources
• 2.5.Forecasting Methodology
• 2.6.Data Triangulation Validation
• 2.7.Assumptions and Limitations

3.Executive Summary

• 3.1.Overview of the Market
• 3.2.Overview of Key Market Segmentations
• 3.3.Overview of Key Market Players
• 3.4.Overview of Key Regions/Countries
• 3.5.Overview of Market Drivers, Challenges, Trends

4.Voice of Customer

5.GlobalIn-vitro Colorectal Cancer Screening Tests MarketOutlook

• 5.1.Market Size Forecast
  • 5.1.1.By Value
• 5.2.Market Share Forecast
  • 5.2.1.By Test Type (Fecal Occult Blood Tests, Biomarker Tests, CRC DNA Screening Tests)
  • 5.2.2.By Region
  • 5.2.3.By Company (2023)
• 5.3.Market Map

6.North America In-vitro Colorectal Cancer Screening Tests Market Outlook

• 6.1.Market Size Forecast
  • 6.1.1.By Value
• 6.2.Market Share Forecast
  • 6.2.1.ByTest Type
  • 6.2.2.By Country
• 6.3.North America: Country Analysis
  • 6.3.1.United States In-vitro Colorectal Cancer Screening Tests Market Outlook
    • 6.3.1.1.Market Size Forecast
      • 6.3.1.1.1.By Value
    • 6.3.1.2.Market Share Forecast
      • 6.3.1.2.1.By Test Type
  • 6.3.2.Canada In-vitro Colorectal Cancer Screening Tests Market Outlook
    • 6.3.2.1.Market Size Forecast
      • 6.3.2.1.1.By Value
    • 6.3.2.2.Market Share Forecast
      • 6.3.2.2.1.By Test Type
  • 6.3.3.Mexico In-vitro Colorectal Cancer Screening Tests Market Outlook
    • 6.3.3.1.Market Size Forecast
      • 6.3.3.1.1.By Value
    • 6.3.3.2.Market Share Forecast
      • 6.3.3.2.1.By Test Type

7.Europe In-vitro Colorectal Cancer Screening Tests Market Outlook

• 7.1.Market Size Forecast
  • 7.1.1.By Value
• 7.2.Market Share Forecast
  • 7.2.1.By Test Type
  • 7.2.2.By Country
• 7.3.Europe: Country Analysis
  • 7.3.1.Germany In-vitro Colorectal Cancer Screening Tests Market Outlook
    • 7.3.1.1.Market Size Forecast
      • 7.3.1.1.1.By Value
    • 7.3.1.2.Market Share Forecast
      • 7.3.1.2.1.By Test Type
  • 7.3.2.United Kingdom In-vitro Colorectal Cancer Screening Tests Market Outlook
    • 7.3.2.1.Market Size Forecast
      • 7.3.2.1.1.By Value
    • 7.3.2.2.Market Share Forecast
      • 7.3.2.2.1.By Test Type
  • 7.3.3.Italy In-vitro Colorectal Cancer Screening Tests Market Outlook
    • 7.3.3.1.Market Size Forecast
      • 7.3.3.1.1.By Value
    • 7.3.3.2.Market Share Forecast
      • 7.3.3.2.1.By Test Type
  • 7.3.4.France In-vitro Colorectal Cancer Screening Tests Market Outlook
    • 7.3.4.1.Market Size Forecast
      • 7.3.4.1.1.By Value
    • 7.3.4.2.Market Share Forecast
      • 7.3.4.2.1.By Test Type
  • 7.3.5.Spain In-vitro Colorectal Cancer Screening Tests Market Outlook
    • 7.3.5.1.Market Size Forecast
      • 7.3.5.1.1.By Value
    • 7.3.5.2.Market Share Forecast
      • 7.3.5.2.1.By Test Type

8.Asia-Pacific In-vitro Colorectal Cancer Screening Tests Market Outlook

• 8.1.Market Size Forecast
  • 8.1.1.By Value
• 8.2.Market Share Forecast
  • 8.2.1.By Test Type
  • 8.2.2.By Country
• 8.3.Asia-Pacific: Country Analysis
  • 8.3.1.China In-vitro Colorectal Cancer Screening Tests Market Outlook
    • 8.3.1.1.Market Size Forecast
      • 8.3.1.1.1.By Value
    • 8.3.1.2.Market Share Forecast
      • 8.3.1.2.1.By Test Type
  • 8.3.2.India In-vitro Colorectal Cancer Screening Tests Market Outlook
    • 8.3.2.1.Market Size Forecast
      • 8.3.2.1.1.By Value
    • 8.3.2.2.Market Share Forecast
      • 8.3.2.2.1.By Test Type
  • 8.3.3.Japan In-vitro Colorectal Cancer Screening Tests Market Outlook
    • 8.3.3.1.Market Size Forecast
      • 8.3.3.1.1.By Value
    • 8.3.3.2.Market Share Forecast
      • 8.3.3.2.1.By Test Type
  • 8.3.4.South Korea In-vitro Colorectal Cancer Screening Tests Market Outlook
    • 8.3.4.1.Market Size Forecast
      • 8.3.4.1.1.By Value
    • 8.3.4.2.Market Share Forecast
      • 8.3.4.2.1.By Test Type
  • 8.3.5.Australia In-vitro Colorectal Cancer Screening Tests Market Outlook
    • 8.3.5.1.Market Size Forecast
      • 8.3.5.1.1.By Value
    • 8.3.5.2.Market Share Forecast
      • 8.3.5.2.1.By Test Type

9.South America In-vitro Colorectal Cancer Screening Tests Market Outlook

• 9.1.Market Size Forecast
  • 9.1.1.By Value
• 9.2.Market Share Forecast
  • 9.2.1.By Test Type
  • 9.2.2.By Country
• 9.3.South America: Country Analysis
  • 9.3.1.Brazil In-vitro Colorectal Cancer Screening Tests Market Outlook
    • 9.3.1.1.Market Size Forecast
      • 9.3.1.1.1.By Value
    • 9.3.1.2.Market Share Forecast
      • 9.3.1.2.1.By Test Type
  • 9.3.2.Argentina In-vitro Colorectal Cancer Screening Tests Market Outlook
    • 9.3.2.1.Market Size Forecast
      • 9.3.2.1.1.By Value
    • 9.3.2.2.Market Share Forecast
      • 9.3.2.2.1.By Test Type
  • 9.3.3.Colombia In-vitro Colorectal Cancer Screening Tests Market Outlook
    • 9.3.3.1.Market Size Forecast
      • 9.3.3.1.1.By Value
    • 9.3.3.2.Market Share Forecast
      • 9.3.3.2.1.By Test Type

10.Middle East and Africa In-vitro Colorectal Cancer Screening Tests Market Outlook

• 10.1.Market Size Forecast
  • 10.1.1.By Value
• 10.2.Market Share Forecast
  • 10.2.1.By Test Type
  • 10.2.2.By Country
• 10.3.MEA: Country Analysis
  • 10.3.1.South Africa In-vitro Colorectal Cancer Screening Tests Market Outlook
    • 10.3.1.1.Market Size Forecast
      • 10.3.1.1.1.By Value
    • 10.3.1.2.Market Share Forecast
      • 10.3.1.2.1.By Test Type
  • 10.3.2.Saudi Arabia In-vitro Colorectal Cancer Screening Tests Market Outlook
    • 10.3.2.1.Market Size Forecast
      • 10.3.2.1.1.By Value
    • 10.3.2.2.Market Share Forecast
      • 10.3.2.2.1.By Test Type
  • 10.3.3.UAE In-vitro Colorectal Cancer Screening Tests Market Outlook
    • 10.3.3.1.Market Size Forecast
      • 10.3.3.1.1.By Value
    • 10.3.3.2.Market Share Forecast
      • 10.3.3.2.1.By Test Type

11.Market Dynamics

• 11.1.Drivers
• 11.2. Challenges

12.Market Trends Developments

• 12.1.Recent Developments
• 12.2.Product Launches
• 12.3.Mergers Acquisitions

13.Global In-vitro Colorectal Cancer Screening Tests Market: SWOT Analysis

14.Competitive Landscape

• 14.1.Abbott Laboratories, Inc.
  • 14.1.1.Business Overview
  • 14.1.2.Product Service Offerings
  • 14.1.3.Recent Developments
  • 14.1.4.Key Personnel
  • 14.1.5. SWOT Analysis
  • 14.1.6. Financials (As reported)
• 14.2.Beckman Coulter, Inc.
• 14.3.Eiken Chemical Co., Ltd.
• 14.4.Sysmex Corporation
• 14.5.Siemens Healthineers AG
• 14.6.Quest Diagnostics Incorporated
• 14.7.Merck KGaA
• 14.8.Kyowa Kirin Co., Ltd.
• 14.9.Randox Laboratories Ltd.
• 14.10.R-Biopharm AG

15.Strategic Recommendations

16.About Us Disclaimer